Theraclion said yesterday its academic development partner, the University of Virginia, won an FDA nod to launch a study of the combined use of echotherapy high intensity focused ultrasound and immunotherapy drug pembrolizumab for treating patients with breast cancer.
The study will examine the combined treatment’s effect on fighting breast cancer tumor cells, the French company said. Theraclion is hopeful that HIFU treatment may locally potentiate immune responses induced by the immunotherapy drugs.
Read the whole story at our sister site, Drug Delivery Business
The post Theraclion partner UVA wins FDA nod for combined HIFU, immunotherapy breast cancer trial appeared first on MassDevice.
from MassDevice http://ift.tt/2sWZeYU
Cap comentari:
Publica un comentari a l'entrada